Metraipolis › archive › dc_4926d260ae4b

Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for… — Europe PMC PMID:42212134

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42212134
DOI
10.3389/fimmu.2026.1817221
License (as archived)
solo-consultazione
Archived
2026-11-02T09:55:21.418Z
SHA-256 of the archived text
07afbfc310a9595ef88f7cd8a04106d1a30a3f2922fcca0cc69d263b2c5e579c
Stable URL of this page
https://metraipolis.com/documento/dc_4926d260ae4b

How to cite

Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for… — Europe PMC PMID:42212134 — Europe PMC (en), https://europepmc.org/article/MED/42212134 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4926d260ae4b (Metraipolis archive dc_4926d260ae4b, sha256 07afbfc310a9595ef88f7cd8a04106d1a30a3f2922fcca0cc69d263b2c5e579c)
BibTeX
@misc{dc4926d260ae4b,
  title = {Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for… — Europe PMC PMID:42212134},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42212134},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4926d260ae4b; sha256 07afbfc310a9595ef88f7cd8a04106d1a30a3f2922fcca0cc69d263b2c5e579c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42212134. Agents can read the archived copy with the MCP tool read_document.